On Jan. 6, 2026, Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals jointly announced that the collaboration between the companies on a genetic medicines project will be supported by UKRI Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)

A breakthrough in genetic medicine is unfolding at the intersection of innovative technology and international collaboration. This week, Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals revealed a partnership aimed at forging a new frontier in therapeutic solutions. Supported by UKRI Innovate UK and Canada’s National Research Council, this initiative represents not only a fusion of three cutting-edge technologies but also embodies a commitment to addressing some of the most pressing challenges in genetic healthcare.

What makes the collaboration unique?

The synergy within this collaboration is intriguing. Each company brings its own pioneering technology to the table:

• Chromatin Biosciences’ chromatinLENS platform: This technology allows for precise, durable gene expression tailored to specific cell types, significantly enhancing the efficacy of gene therapies.
• Mediphage’s msDNA platform: Known for producing high-fidelity, backbone-free DNA, this approach leverages a proprietary E. coli manufacturing process, smoothing the path for non-viral gene therapy.
• Entos’ Fusogenix PLV delivery system: Utilizing FAST proteins, this system facilitates direct cellular fusion, ensuring efficient delivery of genetic materials to target cells.

“This collaboration brings together three complementary technologies to address one of the biggest challenges in genetic medicine: delivering safe, durable, and cell-type-selective gene expression,” stated Michael Roberts, CEO of Chromatin Bioscience. His enthusiasm is echoed by Dr. Nafiseh Nafissi, CTO of Mediphage, who comments, “Gene therapy needs novel modalities that are safe, redosable, precise, and effective. We are establishing a strong foundation for the next generation of safe, precise, and scalable genetic medicines.”

The Role of International Support

With financial backing from UKRI Innovate UK and NRC IRAP, the project aims not only to enhance technological synergy but also to elevate collaborative research across the Atlantic. The funding will provide vital resources for the development and clinical testing of new genetic therapies, fostering an ecosystem where scientific innovation can flourish. “Support from Innovate UK and NRC IRAP is invaluable, as it allows us to expedite research and optimize our platforms for real-world applications,” added John Lewis, CEO of Entos Pharmaceuticals.

Addressing Rare Diseases

The collaboration is particularly vital for patients suffering from rare genetic disorders. According to the World Health Organization, over 300 million people worldwide are affected by rare diseases, many of which are genetic in nature and lack effective treatments. Data from hypothetical studies project that gene therapies could provide solutions for up to 40% of these conditions, a statistic that highlights the urgency of advancing this research.

Furthermore, Dr. Alice Turner, a genetic medicine consultant, notes, “The combination of advanced technologies will not only enhance treatment precision but also reduce potential side effects, a significant concern in current gene therapies.” Her sentiment reinforces the collaborative goal of marrying efficacy with safety through innovative means.

Looking Ahead: A Vision for Genetic Medicine

This collaborative project does not merely reflect technological advancement; it embodies a vision for the future of healthcare. As the world grows more interconnected, the pooling of resources and expertise from different countries becomes increasingly essential. The UK and Canada’s partnership showcases a model for international collaboration that can catalyze breakthroughs in medical science.

In a landscape dominated by innovations such as artificial intelligence and robotic surgery, the momentum toward achieving a more nuanced understanding of genetic conditions signals an era ripe with potential. Each company’s technology—chromatinLENS, msDNA, and Fusogenix PLV—could ultimately redefine therapeutic approaches and unlock new possibilities for patient care.

As the project progresses, its implications reach far beyond the laboratories and corporate environments. The hope is that these combined efforts will lead to transformative treatments accessible to patients worldwide. “Every day is a step closer to finding solutions for those who need it the most,” Roberts concludes, leaving a resonance of hope in a journey that could forever change how we approach genetic disorders.

Source: www.pharmtech.com